First Tracks Biotherapeutics, Inc. - 8-K Filing
First Tracks Biotherapeutics announced positive Phase 1b results for ANB033 in celiac disease, showing statistically significant protection against gluten-induced intestinal damage and symptoms. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TRAX
Read the full article at SEC EDGAR
Part of the story iBio, Inc. - 8-K Filing (3 articles)